LEADER 00000cam  2200481Mi 4500 
001    ocn1107456014 
003    OCoLC 
008    180316t20192018enk      b    001 0 eng d 
020    9781509868087|qpaperback 
020    1509868089 
024 8  40028196876 
041    eng 
082 00 338.7681761|223 
084    BUS025000|aBUS027000|aTEC059000|2bisacsh 
084    Oeb|2kssb/8 
084    Qaacc|2kssb/8 
092 0  338.7|bengelska 
100 1  Carreyrou, John,|4aut 
245 10 Bad blood :|bsecrets and lies in a Silicon Valley startup 
       /|cJohn Carreyrou 
246 30 Secrets and lies in a Silicon Valley startup 
264  1 London :|bPicador,|c2019 
264  4 |c©2018 
300    339 pages ;|c25 cm 
336    text|btxt|2rdacontent 
337    unmediated|bn|2rdamedia 
338    volume|bnc|2rdacarrier 
500    First published 2018 by Alfred A. Knopf, a division of 
       Penguin Random House, New York. This edition published in 
       2019 by Picador, UK 
504    Includes bibliographical references (pages 305-324) and 
       index 
520    In 2014, Theranos founder and CEO Elizabeth Holmes was 
       widely seen as the female Steve Jobs: a brilliant Stanford
       dropout whose startup "unicorn" promised to revolutionize 
       the medical industry with a machine that would make blood 
       tests significantly faster and easier. Backed by investors
       such as Larry Ellison and Tim Draper, Theranos sold shares
       in a fundraising round that valued the company at 9 
       billion dollars, putting Holmes's worth at an estimated 
       4.7 billion dollars. There was just one problem: The 
       technology didn't work. For years, Holmes had been 
       misleading investors, FDA officials, and her own 
       employees. When John Carreyrou, working at The Wall Street
       Journal, got a tip from a former Theranos employee and 
       started asking questions, both Carreyrou and the Journal 
       were threatened with lawsuits. Undaunted, the newspaper 
       ran the first of dozens of Theranos articles in late 2015.
       By early 2017, the company's value was zero and Holmes 
       faced potential legal action from the government and her 
       investors. The biggest corporate fraud since Enron is a 
       cautionary tale set amid the bold promises and gold-rush 
       frenzy of Silicon Valley 
600 10 Holmes, Elizabeth,|d1984- 
610 20 Theranos (Firm)|xHistory 
650  0 New business enterprises|xCorrupt practices|zUnited States
       |vCases 
650  0 Fraud 
650  7 Hematologic equipment industry.|2fast 
650  7 Securities fraud.|2fast 
650  7 Bedrägeri|2sao 
650  7 Bedragare|2sao 
650  7 Industri - ekonomiska aspekter|2sao 
651  4 Förenta staterna 
651  7 United States 
655  7 Trials, litigation, etc.|2fast 
907 00 190828